By Fineline Cube 
France-based Pierre Fabre Laboratories announced the acquisition of global rights to PFL-721 and PFL-241 from Antares Therapeutics, Inc., a spin-off of US-headquartered Scorpion Therapeutics, Inc. Under the agreement, Pierre Fabre will expand its previous deal with Scorpion Therapeutics to obtain full global rights to both assets and lead their clinical development programs.
Assets Overview
PFL-721, a mutation-specific EGFR Exon 20 and HER2 Exon 20 inhibitor, is poised to enter the dose optimization phase of its first-in-human (FIH) trial for non-small cell lung cancer (NSCLC). Meanwhile, PFL-241, a brain-penetrant, fourth-generation EGFR inhibitor targeting the C797S resistance mutation, is currently in the dose-escalation stage of its FIH study for NSCLC patients.
Strategic Expansion
This acquisition marks a significant step in Pierre Fabre’s strategic expansion, enhancing its portfolio with promising candidates in the field of oncology.-Fineline Info & Tech